ISSN:
1573-7373
Keywords:
MX2
;
dissemination
;
malignant glioma
;
intrathecal chemotherapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract We examined whether the intrathecal MX2 chemotherapy for treating dissemination of malignant glioma would be a feasible therapy. In the toxicity study, physiological and histological neurotoxicity was not observed in the rats treated with less than 100 μg/kg of MX2 administered intracisternally. But physiological side effects were observed in the treatment group of more than 200 μg/kg and histological brain toxicity was in the treatment group of more than 1000 μg/kg. Dissemination models were induced in rats by intracisternal inoculation of C6 glioma cells. The median survival times of the rats treated with 100 μg/kg of intrathecal MX2 on day 1, 3, or 7 after tumor inoculation were prolonged by 52.4% (p=0.0006), 31.5% (p=0.0007), and 7.1% (p=0.0180), respectively, compared to that of untreated control animals. Intrathecal MX2 treatment also cured 33.6% of rats in the treatment group. These findings suggested that there was a possibility that intrathecal MX2 would be a safe and effective method for treating dissemination of malignant glioma.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1006436911670
